<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">18270</article-id><article-id pub-id-type="doi">10.7554/eLife.18270</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title><italic>MYC</italic> activation and <italic>BCL2L11</italic> silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-59060"><name><surname>Wood</surname><given-names>C David</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-59061"><name><surname>Veenstra</surname><given-names>Hildegonda</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-59062"><name><surname>Khasnis</surname><given-names>Sarika</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-59063"><name><surname>Gunnell</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-59064"><name><surname>Webb</surname><given-names>Helen M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-59065"><name><surname>Shannon-Lowe</surname><given-names>Claire</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15453"><name><surname>Andrews</surname><given-names>Simon</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-59066"><name><surname>Osborne</surname><given-names>Cameron S</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-48940"><name><surname>West</surname><given-names>Michelle J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9497-9365</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">School of Life Sciences</institution>, <institution>University of Sussex</institution>, <addr-line><named-content content-type="city">Brighton</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><institution content-type="dept">Institute of Immunology and Immunotherapy</institution>, <institution>University of Birmingham</institution>, <addr-line><named-content content-type="city">Birmingham</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff3"><institution content-type="dept">Bioinformatics Group</institution>, <institution>Babraham Institute</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff4"><institution content-type="dept">Department of Genetics and Molecular Medicine</institution>, <institution>King's College London School of Medicine</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1166"><name><surname>Proudfoot</surname><given-names>Nick J</given-names></name><role>Reviewing editor</role><aff><institution>University of Oxford</institution>, <country>United Kingdom</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>m.j.west@sussex.ac.uk</email> (MW);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>04</day><month>08</month><year>2016</year></pub-date><volume>5</volume><elocation-id>e18270</elocation-id><history><date date-type="received"><day>28</day><month>05</month><year>2016</year></date><date date-type="accepted"><day>03</day><month>08</month><year>2016</year></date></history><permissions><copyright-statement>Â© 2016, Wood et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Wood et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-18270-v1.pdf"/><abstract><p>Lymphomagenesis in the presence of deregulated <italic>MYC</italic> requires suppression of <italic>MYC</italic>-driven apoptosis, often through downregulation of the pro-apoptotic <italic>BCL2L11</italic> gene (Bim). Transcription factors (EBNAs) encoded by the lymphoma-associated Epstein-Barr virus (EBV) activate <italic>MYC</italic> and silence <italic>BCL2L11</italic>. We show that the EBNA2 transactivator activates multiple <italic>MYC</italic> enhancers and reconfigures the <italic>MYC</italic> locus to increase upstream and decrease downstream enhancer-promoter interactions. EBNA2 recruits the BRG1 ATPase of the SWI/SNF remodeller to <italic>MYC</italic> enhancers and BRG1 is required for enhancer-promoter interactions in EBV-infected cells. At <italic>BCL2L11</italic>, we identify a haematopoietic enhancer hub that is inactivated by the EBV repressors EBNA3A and EBNA3C through recruitment of the H3K27 methyltransferase EZH2. Reversal of enhancer inactivation using an EZH2 inhibitor upregulates <italic>BCL2L11</italic> and induces apoptosis. EBV therefore drives lymphomagenesis by hijacking long-range enhancer hubs and specific cellular co-factors. EBV-driven <italic>MYC</italic> enhancer activation may contribute to the genesis and localisation of <italic>MYC</italic>-Immunoglobulin translocation breakpoints in Burkitt's lymphoma.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007903</institution-id><institution>Bloodwise</institution></institution-wrap></funding-source><award-id>12035</award-id><principal-award-recipient><name><surname>West</surname><given-names>Michelle J</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007903</institution-id><institution>Bloodwise</institution></institution-wrap></funding-source><award-id>15024</award-id><principal-award-recipient><name><surname>West</surname><given-names>Michelle J</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007903</institution-id><institution>Bloodwise</institution></institution-wrap></funding-source><award-id>14007</award-id><principal-award-recipient><name><surname>Osborne</surname><given-names>Cameron S</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/J002046/1</award-id><principal-award-recipient><name><surname>Shannon-Lowe</surname><given-names>Claire</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="datasets"><title>Major datasets</title><p/><p>The following datasets were generated:</p><p><related-object content-type="generated-dataset" id="dataro1" source-id="To be provided" source-id-type="uri"><collab>C. David Wood</collab>, <collab>Hildegonda Veenstra</collab>, <collab>Sarika Khasnis</collab>, <collab>Andrea Gunnell</collab>, <collab>Helen M. Webb</collab>, <collab>Claire Shannon-Lowe</collab>, <collab>Simon Andrews</collab>, <collab>Cameron S. Osborne and Michelle J. West</collab>, <year>2016</year><x>,</x> <source>MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="To be provided">To be provided</ext-link><x>,</x> <comment>Publicly available at the NCBI Gene Expression Omnibus (accession number: GSE82150)</comment></related-object></p></sec><supplementary-material><ext-link xlink:href="elife-18270-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>